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Abstract  
Patients with respiratory infections are often managed presumptively until confirmation of 
infection status. We assessed the impact of introducing the Enigma® MiniLab™ FluAB-RSV 
point-of-care test (POCT) on patients admitted with a suspected respiratory virus driven 
illness in an acute pediatric ward. This utilized a before (respiratory viral season 2013/14) 
and after (respiratory viral season 2014/15) design. Following POCT implementation, 
oseltamivir prescribing increased in patients with influenza (OR=12.7, p=0.05, 95% CI [1.0, 
153.8]). A reduction in the average reimbursement charges without a change in the length 
of stay was observed. Modelling suggested that savings in laboratory tests costs could be 
achieved if the POCT cost £30 and was used for screening, followed by the respiratory viral 
panel for RSV and influenza negative patients. A rapid POCT for influenza A/B and RSV 
infections in pediatric inpatients may improve oseltamivir prescribing, strengthen 
antimicrobial stewardship, reduce reimbursement charges and decrease laboratory costs, 
even without a reduction in length of stay. 
Keywords 
Respiratory syncytial virus, influenza virus A, influenza virus B, point-of-care technology, 
rapid diagnostic tests 
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Introduction 
Influenza and respiratory syncytial viruses (RSV) are common causes of respiratory infections 
and can be particularly severe in children resulting in significant mortality.(1) In the United 
Kingdom (UK), children aged under 15 years comprise 37% of all influenza-attributable 
hospital admissions.(2) The estimated hospital admission rate for influenza in previously 
healthy children aged under five years reaches 1.9 per 1,000 annually in England and is more 
than five times greater in children aged 5 to 14 who have comorbidities.(2) Influenza-like-
illness (ILI) places a significant burden on healthcare systems.(3) In the United States, over 
600,000 life years are lost, at a cost of $87.1 billion every influenza season.(4)  
 
To reduce risk of hospital transmission, it is recommended that patients suspected of having 
either influenza or RSV infection are presumptively isolated in a side room or are cohorted 
with other patients, until confirmatory testing is available.(5,6) Patients with confirmed 
influenza or those presenting during active influenza season should be offered antiviral 
treatment within 48 hours of symptom onset.(7) However, the prescribing of antivirals 
remains low in hospitalized children with only 9.3-11% of those eligible receiving these 
medications. (8,9) 
 
Centralized laboratory testing of respiratory samples can be slow;(10) reducing turnaround 
time may enable earlier appropriate treatment and / or improved cohorting and isolation 
strategies to prevent transmission. While enzyme immunoassay based point-of-care tests 
(POCTs) for influenza and RSV have been available for several years,  a health technology 
appraisal found little benefit of using these devices in a near-patient setting (11). Moreover, 
these tests have lower sensitivities compared to PCR-based devices. (12–14) A new 
multiplex PCR-based POCT, Enigma® MiniLab™ FluAB-RSV PCR assay (Enigma Diagnostics 
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Ltd, Salisbury, UK), became available in 2015. The performance characteristics of a 
commonly used laboratory based respiratory pathogen panel  (xTAG®) and the POCT assay 
are summarized in Table A1 (Appendix 1, Online Resource 1).(15–17) 
 
We undertook a real-world evaluation to assess the impact of introducing the Enigma® 
MiniLab™ FluAB-RSV POCT in a pediatric ward compared to current care using just the 
laboratory test. This evaluated the length of stay, electronically recorded drug prescriptions 
including oseltamivir and antibiotics, laboratory tests, associated costs of drug prescriptions 
and laboratory tests, and reimbursement charges. 
Materials and methods 
Population and study design 
The evaluation was conducted on the acute pediatric ward of the Evelina London Children’s 
Hospital (Guys and St Thomas NHS Foundation Trust) in patients with suspected ILI (with 
typical symptoms of fever, headache, myalgia, cough, coryza and pharyngitis) or 
bronchiolitis (with typical presentation of one of more of the following; fever, rhinitis, cough, 
increased work of breathing and wheeze). Inpatient admission data was collected during the 
main influenza season between November 1st and February 28th of two consecutive years, 
for patients having a Respiratory Viral Panel (RVP) (xTAG® RVPfast2, Luminex Corp, Austin, 
TX) ordered within 72 hours of admission. Patients admitted during the 2013/14 season 
when only the RVP was used (period 1) were compared (with data collected retrospectively) 
to those during the 2014/15 season, in which both the POCT and the RVP were used in 
parallel (period 2). In period 2, the POCT was available for use 24 hours a day, 7 days a week 
for any patient admitted to Mountain Ward who required a swab taken for respiratory virus 
diagnostic testing. The final sample size was 274 (period 1) and 300 (period 2) (see Appendix 
2 for details, Online Resource 1). Staff were encouraged to act on the POCT result although 
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no formal protocol was introduced.  Study outcomes are presented from the perspective of 
the National Health Service (NHS). Research Ethics Committee approval was waived as this 
was classified as a service evaluation. The manufacturer of the POCT funded the study but 
did not have any role in analysis or reporting of findings. 
Outcomes 
Four outcomes were used to assess the impact of the POCT: length of stay, drug utilization 
(oseltamivir and antibiotics) and overall drug costs, ancillary laboratory test utilization and 
costs, and tariff reimbursement charges for both the total inpatient admission and the 
reimbursement for attributable time spent on the acute pediatric ward.  
Drugs 
Patient level prescribing data that was available in the electronic patient records was 
obtained for the entire hospital stay, including costs of pharmacy supplied items. All 
admissions in which oseltamivir, antibiotics, and immunoglobulins were prescribed were 
identified. The costs of all medications (for that prescribing year, converted to 2014/15 drug 
price) were determined to estimate the average total drug costs per admission. Drugs 
administered from ward stock were not captured in the electronic patient data; these 
potentially relevant antibiotics included amoxicillin, benzylpenicillin, cephalexin, cefotaxime, 
ceftazidime, ceftriaxone, cefuroxime, clarithromycin, clindamycin, co-amoxiclav, 
erythromycin, flucloxacillin, gentamicin, metronidazole, trimethoprim, and vancomycin. 
Laboratory tests  
For each admission, the number of laboratory tests were obtained (12 admissions had no 
test data and were excluded from the analysis of test costs). Prices from the hospital’s 
2014/15 laboratory provider were used (unpublished).  
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Reimbursement charges  
Reimbursement charges represent the payments made to the hospital from payors for 
completed patient admissions. These estimate the standard associated care costs (staff, 
hotel, indirect/overheads, standard diagnostics, medications, and procedures). 
 
Reimbursement charges for admissions in the NHS are coded as Health Care Resource 
Groups (HRG), which are groupings of activities based on the International Classification of 
Disease version 10 (ICD-10) diagnostic codes, and specific procedures and interventions 
performed during an admission.(18) For a given code, factors including admission type 
(elective or emergency presentation), complications, length of stay, and specialized top-up 
services determine the final reimbursement charge. HRG codes and reimbursement charges 
from 2014/15 were used for both periods in the analysis.(18) 
Data analysis 
Descriptive statistics were reported for all eligible admissions during both periods. These 
included age (in months), sex, complications during admission, ‘relevant conditions’, being 
discharged with a respiratory HRG code, admission to the High Dependency Unit (HDU), 
total length of stay, length of stay on the acute pediatric ward, proportion of admissions 
where  oseltamivir, antibiotics and immunoglobulin were prescribed, average total drug 
costs per admission, average number of laboratory tests per admission and per day, average 
total test cost, average total reimbursement charge and average acute pediatric ward 
reimbursement charge.  
A ‘relevant condition’ is defined as an ICD-10 diagnostic code that is either an indication for 
receiving influenza vaccination (19) or is clinically associated with a respiratory infection (see 
Appendix 3, Online Resource 1). This was included to control for conditions that could 
increase the risk of potential complications resulting from, and thereby the cost of, treating 
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an influenza- or RSV-related infection. Certain HRG codes were distinguished as being ‘with 
complications’ as determined by patient acuity and we created a variable to control for that. 
We also created a variable for admissions that were discharged with a respiratory HRG code 
(see Appendix 4, Online Resource 1).  
The proportion of positive results for each virus detected by the RVP in both periods was 
determined. Bivariate tests (χ2 and t-tests for categorical and continuous variables 
respectively) were conducted on all variables to determine whether there were statistically 
significant differences between periods.  
To examine the effect of the use of POCT on the outcome of oseltamivir and antibacterial 
prescribing, we used the admission period as a proxy to estimate the odds ratio (OR) using 
logistic regression. The regression model is shown in Appendix 2, Online Resource 1. We 
also conducted multivariate linear regression analyses to explore the impact of the period 
on average reimbursement charges, and cost of drugs and laboratory tests. Regression 
analyses were controlled for potentially confounding patient characteristics: age, sex, having 
a relevant condition, having a complication, and HDU admission. 
The effect on costs of laboratory tests was modelled if the POCT was used as a ‘gatekeeper’ 
screening test that was always performed before an RVP, i.e. patients with a positive POCT 
would require no further investigation whereas a follow-up RVP would be performed for 
those with a negative POCT. To analyze this, we removed the costs of the RVP tests 
performed in period 2 for patients who tested positive for RSV and /or influenza A/B on 
POCT (see Appendix 5, Online Resource 1). We used an assumed cost of £30 for the POCT 
test. 
To account for the skewed distribution of costs, a logarithmic transformation of cost was 
utilized as the outcome, which is a widely used strategy for analyses with non-normal 
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distributions.(20–23) See Appendix 2 (Online Resource 1) for additional information. All 
analyses were performed in Stata 11 for Windows (STATACorp, College Station, TX) and 
statistical significance was assumed at α = 0.05. 
 
Results 
Descriptive statistics 
Descriptive statistics are presented in Table 1. Patients in period 1 were significantly 
younger (median 19 vs. 26 months, p<0.01) and had a higher occurrence of complications 
(22.3% vs. 13.0%, p<0.01). The prescribing of oseltamivir and antibiotics between the two 
periods did not significantly differ from each other without controlling other potential 
confounders. There was also no evidence of significant differences for the other variables.  
 
There was no significant difference between the periods for the total length of stay (median 
= 2 days for both periods, p=0.23), or length of stay on the acute pediatric ward (median = 2 
days for both periods, p=0.91). The average reimbursement charges were not statistically 
different between periods. There was a slight increase in the number of respiratory HRGs in 
period 2, although it was not significant (51.1% vs. 59.0%, p=0.06).  
 
Table 1. Descriptive statistics of the eligible admissions for periods 1 and 2 
 
Period 1 
(n=274) 
Period 2 
(n=300) 
P-value 
Patient characteristics    
Age – months (median, range) 19 (0-209) 26 (0-224) <0.01 
  0 - 11 months (n, %) 102 (37%) 73 (24%)  
  12 - 59 months (n, %) 123 (45%) 150 (50%)  
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   60 months (n, %) 49 (18%) 77 (26%)  
Female sex (n, %)  110 (40.1) 114 (38.0) 0.60 
With a complication (n, %) a 61 (22.3) 39 (13.0) <0.01 
With a relevant condition (n, %) b 94 (34.3) 103 (34.3) 0.99 
With a respiratory HRG (n, %) c 140 (51.1) 177 (59.0) 0.06 
Requiring hospitalization in the High 
Dependency Unit (HDU) (n, %) 
16 (5.8) 25 (8.3) 0.25 
Length of Stay    
Length of stay – days (median, range) 2 (0-36) 2 (0-116) 0.23 
Length of stay on the acute pediatric ward 
– days (median, range) 
2 (0-36) 2 (0-56) 0.91 
Drug Utilization and Costs    
Admissions with antivirals prescribed (n, %) 15 (5.5) 23 (7.7) 0.29 
Admissions with oseltamivir prescribed (n, 
%) 
12 (4.4) 23 (7.7) 0.10 
Admissions positive for influenza with 
oseltamivir prescribed (n, %) 
2 (13.3) 8 (40.0) 0.08 
Admissions with antibiotics prescribed (n, 
%) 
97 (35.4) 101 (33.7) 0.66 
Admissions with immunoglobulins 
prescribed (n, %) 
7 (2.6) 4 (1.3) 0.29 
Average total drug cost (£, mean ± SD) 145 ± 470 136 ± 318 0.78 
Laboratory Tests Utilization and Costs    
Number of laboratory tests per admission 
(n, mean ± SD) 
24 ± 16 23 ± 17 0.41 
Number of laboratory tests per 
admission day (n, mean ± SD) 
13 ± 8 12 ± 8 0.11 
Average total test cost (£, mean ± SD) 1,251 ± 373 1,219 ± 367 0.31 
Reimbursement Charges    
Average reimbursement charge for the 
entire admission (£, mean ± SD) 
1,468 ± 2,081 1,444 ± 2,484 0.90 
Average reimbursement charge on the 
acute pediatric ward (£, mean ± SD) 
1,355 ± 1,289 1,399 ± 2,421 0.79 
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a. Complication defined as per the HRG discharge code 
b. ICD-10 codes for relevant conditions (C92, D57, D70, D73, D84, G12, G80, G93, I42, I50, 
I67, J18, J20, J44, J45, P27, P28, Q02, Q20, Q21, Q22, Q23, Q25, Q31, Q32, Q62, Q90, Z99). 
Full names can be found in Appendix 3, Online Resource 1  
c. Respiratory HRGs: PA19A, PA14E, PA12Z, PA11Z, PA15A, PA14C, PA14C, PA19B, PA65A. 
Full names can be found in Appendix 4, Online Resource 1 
 
The proportion of positive results for the nine viruses included in the RVP was similar in both 
periods (Table 2), suggesting that overall burden of infection was similar between years.  
 
Table 2. Proportion positive of infections according to the respiratory viral panel 
result, by period a 
Viral panel results 
Period 1 
(n=274) 
Period 2 
(n=300) 
P-value 
Influenza A (%) 15 (5.5) 18 (6.0) 0.79 
Influenza B (%) 0 (0.0) 2 (0.6) 0.18 
Respiratory syncytial virus (%) 65 (23.7) 75 (25.0) 0.74 
Metapneumovirus (%) 10 (3.6) 8 (2.7) 0.50 
Coronavirus (%) 15 (5.5) 13 (4.3) 0.52 
Enterovirus (%) 106 (38.7) 116 (38.7) 0.97 
Adenovirus (%) 10 (3.6) 11 (3.7) 1.00 
Bocavirus (%) 10 (3.6) 14 (5.3) 0.55 
Parainfluenza (%) 13 (4.7) 13 (4.3) 0.81 
No evidence of viral infection (%) 74 (27.4) 73 (24.3) 0.46 
a.  There are cases with multiple viral infections, so total number and percentages do not 
sum to 100% 
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Prescriptions for oseltamivir and antibiotics  
Controlling for other potential confounding factors, the OR of oseltamivir prescription was 
12.7 (p=0.05, 95% CI [1.0, 153.8]) for admissions that were positive for influenza in period 2 
compared to period 1 with marginally statistical significance. We did not observe significant 
differences in non-influenza and non-RSV patients (Table 3). There were no significant 
differences in the OR of antibiotics prescribed between periods in those positive for 
influenza and negative for both influenza and RSV. 
 
Table 3. Odds ratios of prescriptions of oseltamivir and antibiotics between the 
two periods (period 2 compared to period 1) a 
 Admissions positive for 
influenza 
Admissions negative for 
influenza and RSV 
 Odds ratio 
[95% CI] 
P-value 
Odds ratio 
[95% CI] 
P-value 
Admissions with 
oseltamivir prescribed 
12.7 
[1.0, 153.8] 
0.05 
0.7 
[0.3, 2.0] 
0.54 
Admissions with 
antibiotics prescribed 
0.4 
[0.1, 2.7] 
 0.38 
1.0 
[0.6, 1.5] 
0.79 
a. Controlling for age, sex, having at least one relevant condition, having a complication, and 
requiring hospitalization in the high-dependency unit; only showing the odds ratios for the 
variable ‘period’. For complete model output, please see Appendix 6, Online Resource 1. 
Costs 
For patients with a negative influenza and RSV test, we found reductions in the average 
reimbursement charge for both the entire admission and the stay on the acute pediatric 
ward (reductions of £165, p=0.05, 95% CI [-£2, £332] and £148, p=0.05, 95% CI [£1, £295], 
respectively); the cost saving effects remained when we look at all patients (reduction of 
£134, p=0.04, 95% CI [£4, £265] and £126, p=0.03, 95% CI [£10, £242], respectively) (Table 
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4). There was no change in reimbursement for patients with proven influenza or RSV 
infection. There was a small but significant increase in the cost of drugs electronically 
recorded between periods 1 and 2 for admissions in which the patients were positive for 
influenza and/or RSV (£12 increase, p<0.01, 95% CI [-£21, -£3]).  
 
Using simple modelling techniques, savings in the costs of laboratory tests could be realized 
if the POCT were to be used as a screening gateway test followed by an RVP for negative 
influenza/RSV results only, based on the POCT cost £30. The average estimated savings 
would be £44 (p<0.01, 95% CI [£34, £53]) for all admissions, with the biggest difference in 
cost savings in positive influenza/RSV patients (saving of £105, p<0.01, 95% CI [£93, £117]). 
 
Table 4. Average reimbursement charge, and drug cost and lab test cost savings by 
type of patient for period 2 compared to period 1a 
  
Patients with 
influenza and/or RSV  
Patients without 
influenza and RSV 
All patients 
Savings 
[95% CI] 
P-value 
Savings 
[95% CI] 
P-value 
Savings 
[95% CI] 
P-value 
Reimbursement for 
total admission (£) 
50 
[-204, 304] 
0.70 
165 
[-2, 332] 
0.05 
134 
[4, 265] 
0.04 
Reimbursement for 
stay on the acute 
pediatric ward (£) 
74 
[-162, 311] 
0.53 
148 
[1, 295] 
0.05 
126 
[10, 242] 
0.03 
Cost of drugs (£) 
-12b 
[-21, -3] 
<0.01 
0 
[-11, 10] 
0.94 
-3 
[-11, 5] 
0.47 
Modelled costs of lab 
tests (£) (with 
assumed POCT cost of 
£30) 
105 
[93, 117] 
<0.01 
13 
[1, 24] 
0.03 
44 
[34, 53] 
<0.01 
a. Controlling for age, sex, having at least one relevant condition, having a complication, and 
requiring hospitalization in the high-dependency unit 
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b. Negative savings imply an additional cost in the second period with regards to the first 
period. 
Discussion 
This is the first evaluation to use a PCR-based POCT for influenza and RSV in a pediatric 
inpatient ward setting. Although not a randomized control trial, this before and after study 
suggested an increase in more accurate oseltamivir prescribing for patients with influenza 
following the introduction of the POCT, which may be due to improved compliance with 
clinical guidelines.(24) Modelling of the data to account for differences in the patient groups 
between periods 1 and 2 suggested reduced reimbursement charges for patients without 
influenza or RSV despite no observed change in length of stay. We also noted reduced costs 
of laboratory tests for all patients when the POCT was implemented, assuming the POCT was 
£30.  
 
Our results are consistent with prior research showing that a POCT can increase appropriate 
oseltamivir use in a pediatric hospital.(25) This may be because confirmation of diagnosis 
was achieved on admission, thereby allowing clinicians to prescribe oseltamivir within 48 
hours from the onset of symptoms, when it has greatest therapeutic effect.(24) In period 1, 
over 85% of patients with influenza did not receive oseltamivir, which could have had 
negative consequences for patient care; a POCT could enable more timely and effective care 
for these patients. 
 
While we did not observe a significant reduction in oseltamivir prescribing in patients who 
tested negative for influenza and RSV in period 2, an OR of 0.7 indicates a tendency towards 
decreased prescribing. In our real-world evaluation, this observation might be due to 
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clinicians being unfamiliar, and thus less trusting of the POCT and therefore continuing to 
prescribe oseltamivir if there are ongoing signs and symptoms of ILI. 
 
While the result of antibiotic prescription in influenza positive patients did not reach 
statistical significance, the odds of prescribing antibiotics were estimated to halve for those 
positive for influenza in period 2. This compares with a study that evaluated the impact of a 
rapid diagnostics of influenza in the pediatric emergency department setting that detected a 
significant reduction in antibiotic prescription in the group which clinicians were informed of 
the positive results of the flu rapid test.(25) However, in our study many antibiotics could 
have been administered directly through the ward supply and data on their use was 
unavailable to us in the electronic patient records. Hence, we do not know if there was a 
true change in antibiotic use across the time periods, or about the small observed increases 
in drug costs in period 2 for those with influenza and/or RSV. We would hope that a POCT 
might facilitate better antimicrobial stewardship in patients with suspected respiratory viral 
infection, but further studies are needed to assess this. 
 
The average number of laboratory tests ordered remained unchanged between the periods. 
As the estimated test costs decreased in period 2, less expensive follow-up tests may have 
been requested following the POCT result, despite no changes in testing guidelines. This 
change in practice has been observed previously.(25) This suggests that a POCT could 
function as a gateway or screening test to prevent the use of additional or more expensive 
tests, with the benefit of providing a faster result. This could be seen if a POCT is 
implemented in other settings, as performing fewer expensive tests could be cost-saving for 
any healthcare provider treating patients during respiratory season. We could reasonably 
expect results of a similar or greater magnitude to those observed in this study if the POCT 
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was deployed in the Emergency Department and tests were performed before patients 
arrived on the ward.  
 
During period 2, reimbursement charges for the entire admission and for the stay on the 
acute pediatric ward decreased for patients who had negative results for both influenza and 
RSV. As we controlled for all known complications, any resultant residual confounding or 
effect modification should be minimized. There was no observed change in length of stay 
between the periods, suggesting that the changes in the reimbursement are not due to the 
different length of hospital admissions. However, reimbursement charges are determined by 
a range of variables, and it is difficult to specifically attribute the reduction in 
reimbursement to the POCT, although it may have been a factor.  
 
It should be noted that there were differences in the epidemiology of influenza infections in 
2013/14 and 2014/15.  In a report from Public Health England, the peak rate of 
hospitalization (all ages) in 2014 to 2015 (1.9/100,000) was higher than the peak seen during 
2013 to 2014 (0.8/100,000). (26) However, UK sentinel hospital surveillance indicated that 
the proportion of confirmed Influenza A confirmed hospitalized cases in those under the age 
of 17 years was lower in 2014/15 than 2013/14 (22% and 27% respectively). Excess all-cause 
mortality in all age groups increased from 0.2% in 2013/14 to 5.4% in 2014/15. Despite 
these differences, we did not observe any significant differences in the distribution of 
respiratory viruses during the study periods (Table 2). Conversely, we observed a greater 
rate of recorded complications (22.3% vs. 13.0%, p<0.01 for 2013/14 and 2014/15 
respectively) in the study population. 
 
Furthermore, the rate of national uptake of live attenuated influenza vaccine in two and 
three year old’s was lower in 2014/15 (38.5% and 32.9% respectively) compared to 2013/14 
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(42.6% and 39.5% respectively). Overall vaccine effectiveness may also have been different 
for the two periods.(27)  It is not known what these differences may have had on the study 
findings. For example, it is possible that the change in oseltamivir prescribing was influenced 
by the increasing incidence of influenza A and/or increase in all cause excess mortality over 
the two periods. However, as these are national data and these parameters were not 
measured for the study population, it is not possible draw any definitive conclusions. 
 
There are several limitations of this study. First, there are potential unobserved factors 
which might influence the results. For instance, as a before and after evaluation, we did not 
control for unobservable time-varying factors; also, the study was performed while the 
hospital was attempting to improve its coding practices, which may have independently 
contributed to the results.   
 
Second, because of unfamiliarity with the POCT test, clinicians may have still relied on the 
RVP results to make clinical decisions. We believe our results are likely to underestimate the 
true effect that the implementation of the test could have once the test has become 
embedded and trusted by clinicians.  
 
The study was undertaken in one center and findings may not be generalizable. However, in 
terms of resource utilization, we believe that the impact of a POCT in other pediatric 
inpatient wards may be similar to what we observed in this study, given similar patterns of 
influenza and RSV.  
 
Lastly, we were unable to determine whether patients were placed on cohorted or general 
wards, or in isolation beds. This information is not reliably recorded in the patient record, so 
we are unable to assess the impact of a POCT on bed management. Results from a 
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questionnaire conducted at the time of the study suggested that ward staff felt the test 
improved bed management (results available upon request from the authors). We 
recommend conducting a time and motion analysis to capture other cost drivers, such as 
staff time. Further studies should also explore a packaged antimicrobial stewardship 
intervention involving an influenza/RSV POCT, including staff training on best prescribing 
practice following the POCT result. This study demonstrates that POCTs may have the 
potential to improve the appropriateness and efficiency of management of ILI in pediatric 
patients and strengthen antimicrobial stewardship practice. 
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